Walder Wyss advised Sulzer in the acquisition of Haselmeier Group
Sulzer has agreed to acquire the Swiss-German Haselmeier Group for EUR 100 million. Closing of the transaction is planned for the fourth quarter of 2020.
Haselmeier is a leading provider of patented injection systems such as subcutaneous self-injection pens for use in fast growing indications such as reproductive health, growth disorders, osteoporosis and diabetes.
With the acquisition of Haselmeier, Sulzer will complement its healthcare portfolio and leverage its APS expertise in precision injection molding to seize growth opportunities in the fast-growing drug delivery devices market.